Impact of National Comprehensive Cancer Network Guidelines Inclusion of Level 1 Evidence on Insurance Denial for Randomized Controlled Trial Patients with Metastatic Spine Disease
Reports of Practical Oncology and Radiotherapy · 04.12.2024 · 29 (5) · 657-660
DOI: 10.5603/rpor.102822 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Reports of Practical Oncology and Radiotherapy, online erschienen am 04.12.2024. Verfasst von Ulysses G Gardner und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology and Molecular Radiation Sciences, The Johns Hopkins Hospital, Baltimore, United States. Die Arbeit wurde bisher 2-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
Background
The primary treatment of metastatic spine disease is radiation therapy (RT), traditionally conventional external beam RT (EBRT) or stereotactic body RT (SBRT). Until recently, there had been no Level 1 evidence supporting SBRT over EBRT, which has led to difficulties obtaining insurance approval. Publication of the first randomized controlled trial (RCT) comparing SBRT to EBRT for spine metastases [Canadian Cancer Trials Group (CCTG)] helped change this. The results showed superiority of SBRT in pain response; however, the results were not cited by The National Comprehensive Cancer Network (NCCN) until March 24, 2023. We present results from an ongoing RCT to assess the impact of this NCCN inclusion on insurance denials for trial-eligible patients. Materials and methods: The ongoing SPORTSMEN RCT randomizes metastatic spine cancer patients to SBRT versus EBRT. Trial-eligible patients during the first six months were examined to assess if SBRT was denied by insurance before March 24, 2023, versus afterwards. Fisher’s exact test was used to assess for statistical significance.
Results
Prior to CCTG NCCN inclusion, 25% of 12 trial-eligible patients experienced SBRT insurance denial. Following NCCN inclusion, of 8 patients, one (12.5%) has undergone insurance denial of SBRT. These differences were not statistically significant.
Conclusions
The inclusion of Level 1 evidence in the NCCN guidelines has resulted in a numerical halving of spine SBRT insurance denials on a RCT, with the small sample size likely the largest culprit of not meeting statistical significance. These findings illustrate the importance of generating high-quality evidence, followed by timely inclusion into the NCCN guidelines.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Radiation Oncology and Molecular Radiation Sciences, The Johns Hopkins Hospital, Baltimore, United States.
- Department of Radiation Oncology, University Hospitals Seidman Cancer Center, Case Western Reserve University School of Medicine, Cleveland, OH, United States.
- Department of Neurological Surgery, University Hospitals Seidman Cancer Center, Case Western Reserve University School of Medicine, Cleveland, OH, United States.
Förderung
- NCI NIH HHS
Zitieren
APA
Gardner, U. G., Brately, M. M., Zuhour, R. J., Sun, Y., Spratt, D. E., & McClelland, S. (2024). Impact of National Comprehensive Cancer Network Guidelines Inclusion of Level 1 Evidence on Insurance Denial for Randomized Controlled Trial Patients with Metastatic Spine Disease. Reports of Practical Oncology and Radiotherapy, 29(5), 657-660. https://doi.org/10.5603/rpor.102822
Vancouver
Gardner UG, Brately MM, Zuhour RJ, Sun Y, Spratt DE, McClelland S. Impact of National Comprehensive Cancer Network Guidelines Inclusion of Level 1 Evidence on Insurance Denial for Randomized Controlled Trial Patients with Metastatic Spine Disease. Reports of Practical Oncology and Radiotherapy. 2024;29(5):657-660. doi:10.5603/rpor.102822
BibTeX
@article{Gardner2024,
author = {Gardner, Ulysses G and Brately, Melissa M and Zuhour, Raed J and Sun, Yilun and Spratt, Daniel E and McClelland, Shearwood},
title = {Impact of National Comprehensive Cancer Network Guidelines Inclusion of Level 1 Evidence on Insurance Denial for Randomized Controlled Trial Patients with Metastatic Spine Disease},
journal = {Reports of Practical Oncology and Radiotherapy},
year = {2024},
volume = {29},
number = {5},
pages = {657--660},
doi = {10.5603/rpor.102822}
}
EUVIMED